Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts.

Machahua, Carlos; Guler, Sabina A.; Horn, Michael P.; Planas-Cerezales, Lurdes; Montes-Worboys, Ana; Geiser, Thomas K.; Molina-Molina, Maria; Funke-Chambour, Manuela (2021). Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respiratory Research, 8(1) BMJ Publishing Group: Open Access 10.1136/bmjresp-2020-000827

[img]
Preview
Text
Serum_calprotectin_as_new_biomarker.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (761kB) | Preview

BACKGROUND

Non-invasive biomarkers for the assessment of disease severity in idiopathic pulmonary fibrosis (IPF) are urgently needed. Calprotectin belongs to the S-100 proteins produced by neutrophils, which likely contribute to IPF pathogenesis. Calprotectin is a well-established biomarker in inflammatory bowel diseases. In this cross-sectional study, we aimed to establish the potential role of calprotectin as a biomarker in IPF. Specifically, we hypothesised that patients with IPF have higher serum calprotectin levels compared with healthy controls, and that calprotectin levels are associated with disease severity.

METHODS

Blood samples were obtained from healthy volunteers (n=26) and from two independent IPF cohorts (derivation cohort n=26, validation cohort n=66). Serum calprotectin levels were measured with a commercial kit adapted for that purpose and compared between healthy controls and patients with IPF. Clinical parameters, including forced vital capacity, diffusing capacity for carbon monoxide (DLCO) and the Composite Physiologic Index (CPI), were correlated with calprotectin serum levels.

RESULTS

The IPF derivation cohort showed increased serum calprotectin levels compared with healthy controls (2.47±1.67 vs 0.97±0.53 µg/mL, p<0.001). In addition, serum calprotectin levels correlated with DLCO% predicted (r=-0.53, p=0.007) and with CPI (r=0.66, p=0.007). These findings were confirmed in an independent IPF validation cohort.

CONCLUSION

Serum calprotectin levels are significantly increased in patients with IPF compared with healthy controls and correlate with DLCO and CPI. Calprotectin might be a potential new biomarker for disease severity in IPF.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Pneumologie (Erwachsene)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Machahua Huamani, Carlos Esteban; Guler, Sabina; Horn, Michael; Geiser, Thomas and Funke-Chambour, Manuela

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2052-4439

Publisher:

BMJ Publishing Group: Open Access

Language:

English

Submitter:

Karin Balmer

Date Deposited:

28 Jan 2021 10:17

Last Modified:

11 Mar 2021 19:57

Publisher DOI:

10.1136/bmjresp-2020-000827

PubMed ID:

33451989

Uncontrolled Keywords:

interstitial fibrosis

BORIS DOI:

10.48350/151443

URI:

https://boris.unibe.ch/id/eprint/151443

Actions (login required)

Edit item Edit item
Provide Feedback